Literature DB >> 17620489

Pooled analysis of tobacco use and risk of Parkinson disease.

Beate Ritz1, Alberto Ascherio, Harvey Checkoway, Karen S Marder, Lorene M Nelson, Walter A Rocca, G Webster Ross, Daniel Strickland, Stephen K Van Den Eeden, Jay Gorell.   

Abstract

CONTEXT: Epidemiologic studies have reported that cigarette smoking is inversely associated with Parkinson disease (PD). However, questions remain regarding the effect of age at smoking onset, time since quitting, and race/ethnicity that have not been addressed due to sample size constraints. This comprehensive assessment of the apparent reduced risk of PD associated with smoking may provide important leads for treatment and prevention.
OBJECTIVE: To determine whether race/ethnicity, sex, education, age at diagnosis, and type of tobacco modify the observed effects of smoking on PD. DESIGN, SETTING, AND PARTICIPANTS: We conducted the first ever pooled analysis of PD combining individual-level data from 8 US case-control and 3 cohort studies (Nurses' Health Study, Health Professionals Follow-Up Study, and Honolulu-Asia Aging Study) conducted between 1960 and 2004. Case-control studies provided data for 2328 PD cases and 4113 controls matched by age, sex, and ethnicity; cohort studies contributed 488 cases and 4880 controls selected from age- and sex-matched risk sets. MAIN OUTCOME MEASURE: Incident PD.
RESULTS: We confirmed inverse associations between PD and smoking and found these to be generally stronger in current compared with former smokers; the associations were stronger in cohort than in case-control studies. We observed inverse trends with pack-years smoked at every age at onset except the very elderly (>75 years of age), and the reduction of risk lessened with years since quitting smoking. The risk reductions we observed for white and Asian patients were not seen in Hispanic and African American patients. We also found an inverse association both for smoking cigars and/or pipes and for chewing tobacco in male subjects.
CONCLUSIONS: Our data support a dose-dependent reduction of PD risk associated with cigarette smoking and potentially with other types of tobacco use. Importantly, effects seemed not to be influenced by sex or education. Differences observed by race and age at diagnosis warrant further study.

Entities:  

Mesh:

Year:  2007        PMID: 17620489     DOI: 10.1001/archneur.64.7.990

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  128 in total

1.  [Perioperative management and anesthesia in Parkinson's disease : interdisciplinary challenge].

Authors:  H Fink
Journal:  Anaesthesist       Date:  2012-02       Impact factor: 1.041

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 4.  Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches.

Authors:  Daniel Garzón; Ricardo Cabezas; Nelson Vega; Marcos Ávila-Rodriguez; Janneth Gonzalez; Rosa Margarita Gómez; Valentina Echeverria; Gjumrakch Aliev; George E Barreto
Journal:  J Mol Neurosci       Date:  2016-01-23       Impact factor: 3.444

5.  Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Authors:  Annie J Lee; Yuanjia Wang; Roy N Alcalay; Helen Mejia-Santana; Rachel Saunders-Pullman; Susan Bressman; Jean-Christophe Corvol; Alexis Brice; Suzanne Lesage; Graziella Mangone; Eduardo Tolosa; Claustre Pont-Sunyer; Dolores Vilas; Birgitt Schüle; Farah Kausar; Tatiana Foroud; Daniela Berg; Kathrin Brockmann; Stefano Goldwurm; Chiara Siri; Rosanna Asselta; Javier Ruiz-Martinez; Elisabet Mondragón; Connie Marras; Taneera Ghate; Nir Giladi; Anat Mirelman; Karen Marder
Journal:  Mov Disord       Date:  2017-06-22       Impact factor: 10.338

6.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

7.  Constraints on data sharing: experience from the nurses' health study.

Authors:  Graham A Colditz
Journal:  Epidemiology       Date:  2009-03       Impact factor: 4.822

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

Review 9.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

10.  Population-based prospective study of cigarette smoking and risk of incident essential tremor.

Authors:  Elan D Louis; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.